NASDAQ:CEMI - Chembio Diagnostics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$11.10 -0.05 (-0.45 %)
(As of 07/20/2018 08:00 AM ET)
Previous Close$11.15
Today's Range$11.10 - $11.22
52-Week Range$5.75 - $11.23
Volume21,100 shs
Average Volume27,876 shs
Market Capitalization$157.91 million
P/E Ratio-21.35
Dividend YieldN/A
Beta1.33
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC for the development of a POC diagnostic test for traumatic brain injury; international diagnostics company to develop a POC diagnostic test for a specific type of cancer; and AstraZeneca for the development of a POC assay for a novel biomarker, as well as with LumiraDx to develop POC diagnostic tests. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

Receive CEMI News and Ratings via Email

Sign-up to receive the latest news and ratings for CEMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CEMI
CUSIPN/A
Phone631-924-1135

Debt

Debt-to-Equity RatioN/A
Current Ratio5.17
Quick Ratio3.86

Price-To-Earnings

Trailing P/E Ratio-21.35
Forward P/E Ratio-50.45
P/E GrowthN/A

Sales & Book Value

Annual Sales$24.01 million
Price / Sales6.55
Cash FlowN/A
Price / CashN/A
Book Value$1.06 per share
Price / Book10.47

Profitability

EPS (Most Recent Fiscal Year)($0.52)
Net Income$-6,370,000.00
Net Margins-21.28%
Return on Equity-32.21%
Return on Assets-25.72%

Miscellaneous

Employees165
Outstanding Shares14,160,000
Market Cap$157.91

Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions

What is Chembio Diagnostics' stock symbol?

Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."

How were Chembio Diagnostics' earnings last quarter?

Chembio Diagnostics Inc (NASDAQ:CEMI) announced its earnings results on Wednesday, May, 9th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.09. The company earned $7.72 million during the quarter, compared to analyst estimates of $6.10 million. Chembio Diagnostics had a negative net margin of 21.28% and a negative return on equity of 32.21%. View Chembio Diagnostics' Earnings History.

What price target have analysts set for CEMI?

1 analysts have issued 12 month price objectives for Chembio Diagnostics' shares. Their predictions range from $14.00 to $14.00. On average, they expect Chembio Diagnostics' share price to reach $14.00 in the next twelve months. This suggests a possible upside of 26.1% from the stock's current price. View Analyst Ratings for Chembio Diagnostics.

What is the consensus analysts' recommendation for Chembio Diagnostics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Chembio Diagnostics' key competitors?

Who are Chembio Diagnostics' key executives?

Chembio Diagnostics' management team includes the folowing people:
  • Mr. John J. Sperzel III, Pres, CEO & Director (Age 54)
  • Mr. Neil A. Goldman, Exec. VP & CFO (Age 50)
  • Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 51)
  • Ms. Sharon Klugewicz, Pres of Americas Region (Age 50)
  • Dr. Robert Passas Ph.D., Pres of EMEA and APAC Regions (Age 64)

Has Chembio Diagnostics been receiving favorable news coverage?

News articles about CEMI stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Chembio Diagnostics earned a news impact score of 0.14 on Accern's scale. They also assigned news articles about the company an impact score of 45.13 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Chembio Diagnostics?

Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chembio Diagnostics' stock price today?

One share of CEMI stock can currently be purchased for approximately $11.10.

How big of a company is Chembio Diagnostics?

Chembio Diagnostics has a market capitalization of $157.91 million and generates $24.01 million in revenue each year. The company earns $-6,370,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Chembio Diagnostics employs 165 workers across the globe.

How can I contact Chembio Diagnostics?

Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at [email protected]


MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  87 (Vote Outperform)
Underperform Votes:  91 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.